As part of its continued commitment to developing next-generation cancer therapeutics, Ocean Biomedical is initiating ...

Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

In this video, Xiuning Le, MD, PhD, discusses how the definition of EGFR-mutated lung cancer has expanded in recent years.

EGFR-TKI 已成为 EGFR 突变晚期非小细胞肺癌（NSCLC）患者的标准治疗方案[1]，然而，约 2%~5% 的初治 EGFR 突变晚期 NSCLC 患者合并原发 MET 扩增，且接受 EGFR-TKI ...

Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer. During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key ...

Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.

7 In January 2025, the European Commission (EC) approved a marketing authorisation for lazertinib, in combination with amivantamab, for the first-line treatment of adult patients with advanced ...

Women have a higher likelihood of having hormone receptor (HR+) non-small cell lung cancer (NSCLC) than men, and mutations of EGFR and KRAS were more common in HR+ NSCLC in a recent study.

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...